Start Your Free Review
Answer 2-3 quick questions to review your potential case.
When CTCL Becomes Fatal: The Richardson Case and Beyond
Cutaneous T-cell lymphoma is an indolent disease in its early stages, but advanced CTCL — particularly large-cell transformation, Sezary syndrome, and visceral involvement — carries high mortality. Stage IVB CTCL has a median survival of approximately 1 to 2 years. When a Dupixent patient's CTCL progresses to these advanced stages and the patient dies, the litigation shifts from personal injury to wrongful death and estate claims.
Richardson v. Sanofi US Inc. et al., filed in the Western District of Tennessee in October 2025, was among the earliest named Dupixent CTCL lawsuits nationally. The case brought public attention to the fatal trajectory that Dupixent-associated CTCL can follow: a patient treated for atopic dermatitis who developed lymphoma during treatment and experienced rapid disease progression. The Richardson filing catalyzed additional lawsuits and contributed to the JPML petition for MDL consolidation.
Fatal CTCL cases carry the highest damage potential in Dupixent litigation. Juries are confronted with a patient who sought relief from a skin condition and instead received a death sentence from a cancer that the manufacturer knew — or should have known — was a risk of its product. The emotional impact of these cases during bellwether trial selection makes wrongful death claims particularly valuable to plaintiffs' steering committees in MDL proceedings.
Wrongful Death vs. Survival Action: Two Separate Claims
A wrongful death claim is brought by the decedent's surviving family members (or a personal representative on their behalf) and compensates the survivors for their own losses: loss of the decedent's companionship, guidance, and consortium; loss of the decedent's financial contributions and earning capacity; and funeral and burial expenses. The claim belongs to the survivors, not to the estate, and the damages reflect the impact of the death on the living.
A survival action, by contrast, is brought by the decedent's estate and recovers damages that the patient could have recovered had they survived: pain and suffering from diagnosis through death, medical expenses incurred during treatment, lost wages during illness, and emotional distress. The survival action essentially 'survives' the decedent's death and passes to the estate. In most jurisdictions, both claims can be pursued simultaneously, and the combined damages from a wrongful death claim plus survival action can significantly exceed a living plaintiff's personal injury recovery.
Who Has Standing to File
Wrongful death standing is controlled entirely by state law, and the rules vary dramatically. In most states, a surviving spouse and minor children have automatic standing. In some states, adult children, parents, and even siblings or domestic partners may also bring wrongful death claims. A handful of states restrict standing to the personal representative of the estate, who files on behalf of all statutory beneficiaries. In states like Alabama, the wrongful death claim is punitive only — it compensates nothing for the survivors' loss but instead punishes the defendant, with the entire recovery going to the estate.
For Dupixent wrongful death claims, identifying the correct state law is critical. The applicable law is typically the state where the death occurred or the state where the decedent was domiciled. If the patient was treated in one state, moved to another for hospice care, and died in a third state, choice-of-law analysis may determine which state's wrongful death statute applies. An attorney experienced in pharmaceutical wrongful death must evaluate standing, applicable law, and filing deadlines before the relevant statute of limitations expires.
State Statute of Limitations Variations for Wrongful Death
Wrongful death statutes of limitations are separate from personal injury SOLs and are typically measured from the date of death, not from the date of diagnosis. Tennessee's wrongful death SOL is 1 year from the date of death — the shortest in the nation. California allows 2 years. New York allows 2 years. Illinois allows 2 years under the Wrongful Death Act but 1 year under the Survival Act if the decedent had not filed suit before death. Florida allows 2 years. Pennsylvania allows 2 years. These tight deadlines mean that families grieving a Dupixent-related death have limited time to consult counsel and file suit.
The discovery rule may extend these deadlines in some states if the family did not know — and could not reasonably have known — that Dupixent caused or contributed to the CTCL that led to death. However, as Dupixent CTCL litigation gains media attention and MDL proceedings publicize the risk, courts may be less willing to apply the discovery rule to new claimants. Families should not assume they have time; the safest course is to consult a pharmaceutical liability attorney within months of a Dupixent patient's death from CTCL.
Damages in Fatal Dupixent CTCL Cases
Damages in fatal CTCL cases encompass multiple categories. The survival action component includes the patient's pre-death pain and suffering — which in advanced CTCL can involve total-body erythroderma, severe pruritus, repeated hospitalizations, chemotherapy, radiation, and stem cell transplantation — plus all medical costs from diagnosis through death. The wrongful death component includes loss of financial support (often calculated using vocational economists who project lifetime earnings), loss of household services, loss of parental guidance for minor children, loss of consortium for a surviving spouse, and funeral expenses.
Punitive damages are available in both wrongful death and survival actions in most jurisdictions, and the fatal nature of the injury supports a strong punitive case. Evidence that Sanofi and Regeneron knew of the CTCL signal, failed to warn, and continued aggressive marketing to expand Dupixent's patient base supports a finding of the reckless disregard or conscious indifference required for punitive awards. Combined wrongful death and survival action damages in fatal pharmaceutical cases routinely reach eight figures in jury verdicts.
Frequently Asked Questions
Related Pages
CTCL Diagnosis After Dupixent Use
Cutaneous T-cell lymphoma is a rare and aggressive blood cancer that masquerades as eczema, psoriasis, and other benign skin conditions — making it uniquely dangerous for Dupixent patients who already carry dermatitis diagnoses. Misdiagnosis rates exceed 40 percent in early-stage CTCL because the symptoms overlap so precisely with the conditions Dupixent is prescribed to treat. Dermatologists expect itchy, red patches in their Dupixent patients; what they may not expect is that those patches now harbor malignant T-cells. Staging ranges from IA (limited patches) to IVB (visceral organ involvement and blood-borne Sezary cells), and the difference between a Stage IA diagnosis and a Stage IIB diagnosis can mean the difference between a normal life expectancy and a five-year survival rate below 40 percent. The critical diagnostic tool is a skin biopsy with immunohistochemistry, which can reveal hallmark Pautrier microabscesses — clusters of malignant T-cells in the epidermis that do not appear in benign dermatitis. Every Dupixent patient whose skin condition worsens, changes character, or fails to respond to continued treatment should demand a biopsy, not another refill.
Dupixent Eye Problems and Ocular Side Effects
Conjunctivitis is the most common adverse event associated with Dupixent, occurring in approximately 30 percent of atopic dermatitis patients in clinical trials — a rate ten times higher than placebo. But conjunctivitis is just the visible surface of a broader ocular toxicity profile that includes blepharitis, keratitis, dry eye syndrome, limbal stem cell deficiency, and in rare but devastating cases, corneal perforation requiring emergency surgical intervention. These eye problems often develop within the first three months of treatment and can persist even after Dupixent is discontinued. Sanofi and Regeneron have acknowledged conjunctivitis on the Dupixent label but have minimized the severity spectrum, leading patients and prescribers to underestimate the risk of serious, vision-threatening complications. For patients who have suffered permanent vision impairment, corneal scarring, or required corneal transplantation due to Dupixent-related ocular injury, the manufacturer's characterization of these events as manageable side effects is contradicted by their clinical experience.
Dupixent MDL Status and Litigation Update
The Judicial Panel on Multidistrict Litigation (JPML) is considering a petition to consolidate all federal Dupixent CTCL lawsuits into a single MDL for coordinated pretrial proceedings. As of early 2026, over 250 individual lawsuits have been filed across multiple federal districts, with plaintiffs proposing consolidation in the Northern District of Georgia (Atlanta) and defendants advocating for the Southern District of New York. MDL No. 3180 would centralize discovery, expert qualification (Daubert) proceedings, and bellwether trial selection under a single transferee judge. For individual plaintiffs, MDL consolidation means coordinated case management and potential leverage from shared discovery, but it also means potential delays as the court works through lead case selection and common issues. The venue decision — Atlanta versus New York versus other candidates — will shape the litigation's procedural landscape, judicial temperament, jury pool demographics, and ultimately the pressure on Sanofi and Regeneron to negotiate a global settlement.
Dupixent Pediatric Use and CTCL Risk in Children
Sanofi and Regeneron have aggressively expanded Dupixent's pediatric indications, securing FDA approval for atopic dermatitis in children as young as 6 months old in 2022, following earlier approvals for ages 6 to 11 in 2020 and adolescents aged 12 to 17 in 2019. This expansion exposed millions of children with developing immune systems to a biologic drug that blocks IL-4 and IL-13 — cytokines critical to immune maturation, T-cell differentiation, and tumor surveillance. While CTCL is rare in children overall, the long-term consequences of sustained immune modulation during critical developmental windows are unknown because Sanofi's pediatric trials were not designed to detect rare cancers and follow-up periods were insufficient to capture latent malignancies. Pediatric Dupixent claims carry unique urgency: children have longer remaining lifespans over which to develop delayed-onset lymphoma, the immune insult occurs during a period of rapid lymphocyte development, and parents made treatment decisions based on safety assurances that did not account for the emerging CTCL signal. The duty to warn is heightened for pediatric drugs because parents — not the patient — make the consent decision, and they deserve complete risk information to exercise informed judgment.
Dupixent Lawsuit Lawsuit
Dupixent (dupilumab) is a monoclonal antibody biologic drug developed by Regeneron Pharmaceuticals and marketed jointly with Sanofi-Aventis and its subsidiary Genzyme Corporation. The FDA first approved Dupixent in March 2017 for adults with moderate-to-severe atopic dermatitis (eczema) who had not responded adequately to topical treatments. Subsequent FDA approvals expanded its use to moderate-to-severe asthma in October 2018, chronic rhinosinusitis with nasal polyps (CRSwNP) in June 2019, eosinophilic esophagitis (EoE) in May 2022, prurigo nodularis in September 2022, and chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype in September 2024. With more than 37 million prescriptions dispensed globally, Dupixent became one of the best-selling biologic drugs in the world, generating over $13 billion in annual revenue for its manufacturers. The drug works by inhibiting interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling — two cytokines that drive type 2 inflammation. While this mechanism was considered targeted and relatively safe, post-market surveillance and independent research have identified a concerning association between Dupixent use and cutaneous T-cell lymphoma (CTCL). CTCL is a rare cancer in which T-cells become malignant and attack the skin, often presenting initially as rashes or patches that can be mistaken for eczema. The critical concern is that symptoms of CTCL closely mimic the very conditions Dupixent is prescribed to treat, potentially masking the cancer and delaying diagnosis. A peer-reviewed study analyzing 19,612 patients found that Dupixent users faced a 4.5 times higher risk of developing CTCL compared to patients not using the drug. The FDA placed Dupixent on its drug safety watchlist in March 2025 and escalated to a formal investigation in September 2025 after receiving over 300 adverse event reports related to lymphoma and blood cancers. As of February 2026, individual lawsuits are being filed against Regeneron Pharmaceuticals, Sanofi-Aventis, and Genzyme Corporation. Plaintiffs allege that the manufacturers knew or should have known about the cancer risk and failed to adequately warn patients and prescribing physicians. Specific allegations include failure to warn, defective design of the drug's labeling, negligence in post-market surveillance, and fraudulent concealment of safety data. A wrongful death suit was filed in Tennessee in October 2025 on behalf of Chandra Richardson. Additional cases have been filed in Florida (January 2026) and Illinois (December 2025). Legal experts anticipate that the Judicial Panel on Multidistrict Litigation will consolidate federal cases into an MDL within the next 12 months.
View full case overview